

III YOUNG RESEARCHERS MEETING

14 - 15 DECEMBER, ONLINE

CIBERONC

PROGRAMME

Sponsored by

December 14th 2020

08:45 - Welcome

- **Anna Bigas Salvans.** Scientific Director of CIBERONC
- **Amparo Cano García & Gema Moreno Bueno.** Training and Mobility Programme Coordinator

09:00 - Respiratory Tract Tumours Research Programme

Chair: *Eva M^a Verdugo Sivianes*

- **Rodrigo Entrialgo Cadierno.** Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra. Luis Montuenga Group. *The phosphatidylinositol transfer protein PTPNC1, functional role and clinical implications in mutant KRAS lung adenocarcinoma.*
- **Irati Macaya Erro.** Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra. Luis Montuenga Group. *Integration of drug repurposing and combinatorial screening identifies novel therapies in mutant KRAS lung cancer.*

09:30 - Breast Cancer Research Programme

Chair: *Manuel Gámez Chiachio*

- **Birlipta Pattanayak.** Instituto de Investigación Sanitaria INCLIVA. Ana Lluch Group. *Oncofoetal gene SALL4: a potential marker for Trastuzumab resistance HER2+ Breast Cancer.*
- **Enrique Javier Arenas Lahuerta.** Vall d'Hebron Instituto de Oncología (VHIO). Joaquín Arribas Group. *JAK2 downmodulation leads to interferon gamma deficient response and resistance to immunotherapy in breast cancer.*

10:00 - Round Table: Women in science

Chairs: *Claudia Coscia Requena & Sandra Díez Villares*

- **María Salazar Roa.** Group Leader at Universidad Complutense Madrid and CNIO, Spain
- **Marisol Soengas González.** Group Leader at CNIO
- **Marta Macho Stadler.** Group Leader at Universidad del País Vasco, Spain and Science Communicator
- **Núria Salán Ballesteros.** Professor at UPC, Spain, president of SCT and Science Communicator

11:00 - Break

11:15 - Gastrointestinal Tumours Research Programme

Chair: *Claudia Coscia Requena*

- **Júlia Canet Hermida.** Instituto de Investigación Biomédica de Bellvitge. Gabriel Capellà Group. *Preliminary evaluation of highly sensitive assessment of microsatellite instability as a tool for cancer risk individualization in Lynch syndrome.*
- **Silvia Pineda San Juan.** Centro Nacional de Investigaciones Oncológicas (CNIO). Núria Malats Group. *Landscape of tumor-infiltrating B and T cell repertoire in pancreatic cancer.*

11:45 - Poster session

Chair: *Noelia Dasilva Freire*

12:30 - Round Table: Mental health during PhD

Chairs: *Manuel Gámez Chiachio & Pilar Bustamante Madrid*

- **Fernando T. Maestre Gil.** Group Leader at Universidad de Alicante, Spain
- **Miguel Ángel Sorrel Luján.** Assistant Professor at Universidad Autónoma de Madrid, Spain
- **Yorick Peterse.** Biomedical and Mental Health Scientist

13:30 - Closing remarks

Chair: *Sandra Díez Villares*

December 15th 2020

08:55 - Welcome

09:00 - Haematological Tumours Research Programme

Chair: Noelia Dasilva Freire

- **Catarina Alexandra Da Silva Maia.** Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra. Jesús San Miguel Group. *Immunologic characterization of Coronavirus Disease 2019 (COVID-19) patients with hematological cancer: biologic and clinical significance.*
- **Cristina López González.** Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS). Elías Campo Group. *Mutational profile and Copy Number Alterations of Follicular Lymphoma patients with different clinical behavior.*

09:30 - Low Prevalence Tumours Research Programme

Chair: Sandra Díez Villares

- **Cristina Megino Luque.** Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifarré (IRBLleida). Xavier Matías-Guiu Group. *Study of ARID1A context-dependent functions in endometrial cancer.*
- **Carmen Salguero Aranda.** Instituto de Biomedicina de Sevilla (IBIS). Enrique de Álava Group. *Analysis of NAB2-STAT6 gene fusion in 87 cases of Solitary Fibrous Tumor: concordance molecular-testing study and novel STAT6 fusion partners.*

10:00 - Mechanisms of Tumour Progression Research Programme

Chair: Pilar Bustamante Madrid

- **Néstor Tirado Cabrera.** Instituto de Investigación contra la Leucemia Josep Carreras (IJC). Anna Bigas Group. *Development of CAR-DOT cells for allogeneic cancer immunotherapy of AML.*
- **Laura Bozal Basterra.** Centro de Investigación Cooperativa en Biociencias (CIC bioGUNE). Arkaitz Carracedo Group. *Luzp1 is a novel regulator of cell division, migration and invasion through the actin cytoskeleton.*

10:30 - Break

10:45 - Plenary Lecture

Chair: Amparo García Cano

Professor Mariano Barbacid. *Targeting KRAS mutant cancers: an urgent medical need.*

11:30 - Poster session

Chair: Claudia Coscia Requena

12:15 - Round Table: Future perspectives after PhD

Chair: Noelia Dasilva Freire & Eva Mª Verdugo Sivianes

- **Ángela Bernardo Álvarez.** Science Journalist at Fundación Ciudadana Civio
- **Antonio Lucena Cacace.** Postdoctoral Researcher at Center for iPS Cell Research and Application (CiRA), Japan
- **Clara León Annicchiarico.** Medical Science Liaison Immunology at Sanofi Genzyme, Spain

13:15 - Challenge

Contest with some questions about the oral communications open to everyone with some prizes as a reward.

Chair: Manuel Gámez Chiachio

13:45 - Awards & Closing Ceremony

Chairs: Pilar Bustamante Madrid & Eva Mª Verdugo Sivianes

14:15 - Tribute to Amparo Cano

14:30 - Closure

Poster programme

Breast Cancer Research Programme

- BC01. Genesets defining sensitivity to Trastuzumab. *Díaz-Gil L, Brasó F, Prat A, Ocaña A, Gyorffy B, Pandiella A.*
- BC02. Evaluation and characterization of the Ovarian Cancer proteome. *Nieto-Jiménez C, Montero JC, Azkargorta M, Elortza F, Ocaña A, Pandiella A.*
- BC03. Cellular localization and function of TGF- α in Kidney Cancer. *Romero-Pérez I, García-Alonso S, Gandullo-Sánchez L, Ocaña A, Montero JC, Pandiella A.*
- BC04. Looking for new mechanisms of resistance to T-DM1 in Breast Cancer cell lines previously resistant to Trastuzumab. *Gandullo-Sánchez L and Pandiella A.*
- BC05. Factors contributing to the engraftment of patient-derived xenografts (PDXs) from Breast Cancer patients and evaluation of efficacy of three chemotherapy agents (doxorubicin, carboplatin, docetaxel) in PDXs from triple negative breast cancer (TNBC) patients. *Bernat R, Ramos-Medina R, Lopez-Tarruella S, García-Saenz JA, Del Monte-Millán M, Cebollero M, Moreno F, Gómez-Haba E, Bueno O, Massarrah T, Echavarria I, Jerez Y, Herrero B, Asensio F, Martin M.*
- BC06. Nanoporous anodic alumina-based sensor for miR-99a-5p detection as an effective early Breast Cancer diagnostic tool. *Garrido-Cano I, Pla L, Santiago-Felipe S, Simón S, Ortega B, Bermejo B, Lluch A, Cejalvo J.M, Eroles P, Martínez-Máñez R.*
- BC07. Understanding the role of Loxl3 in melanogenesis and DNA damage. *Vázquez-Naharro A, Bustos J, Portillo F, Santamaría P.G, Cano A.*
- BC08. Circulating miR-30b-5p in plasma as a potential biomarker for early detection of Breast Cancer. *Adam-Artigues A, Garrido-Cano I, Simón S, Ortega B, Moragón S, Lameirinhas A, Constâncio V, Salta S, Burgués O, Bermejo B, Henrique R, Lluch A, Jerónimo C, Eroles P, Cejalvo JM.*
- BC09. Decoding the Genomic landscape of a high-grade ambiguous endometrial carcinoma: looking for a personalized treatment. *Oltra S, Mota A, Selenica P, Moiola C.P, Casas-Arozamena C, López-Gil C, Gatius S, Ruiz-Miro M, Calvo A, Rojo-Sebastián A, Hurtado P, Piñeiro R, Colas E, Gil-Moreno A, Reis-Filho JS, Matias-Guiu X, Weigelt B, Moreno-Bueno G.*

- BC10. Impact of MEK5 and ERK5 mutations in cancer. *Vicente-Almazán SM, Sánchez-Fernández A, Guillén-Pérez YM, Esparís-Ogando A.*
- BC11. Gasdermin B over-expression arbitrates the HER2-targeted therapy resistance through protective autophagy induction. *Gámez-Chiachio M, Molina-Crespo A, Martínez L, Sarrió D, Moreno-Bueno G.*
- BC12. The antigen target is critical in the mechanism of resistance to T-cell based targeted therapies. *Martínez-Sabadell A, Arenas EJ, Morancho B, Rius I, Escorihuela M, Luque A, Arribas J.*

Gastrointestinal Tumours Research Programme

- GIT01. Circulating cell-free DNA-based liquid biopsy markers for the non-invasive prognosis and monitoring of metastatic Pancreatic Cancer. *Toledano Fonseca M, Cano MT, Inga E, Rodríguez-Alonso R, Gómez España MA, Guil-Luna S, Mena R, de la Haba-Rodríguez JR, Rodríguez-Ariza A, Aranda E.*
- GIT02. Metabolomics profiling of breast cancer patients treated with neoadjuvant therapy. *Zapater-Moros A, Díaz-Beltrán L, Gámez-Pozo A, Trilla-Fuertes L, Lumbreras-Herrera MI, López-Camacho E, Espinosa E, Zamora P, Sánchez-Rovira P, Fresno-Vara JA.*
- GIT03. Screening of CNVs using NGS data improves mutation detection yield and decreases costs in genetic testing for hereditary cancer. *Moreno-Cabrera JM, del Valle J, Feliubadaló L, Pineda M, González S, Campos O, Cuesta R, Brunet J, Serra E, Capellá G, Gel B, Lázaro C.*
- GIT04. Assessing effectiveness of colonic and gynaecological risk reducing surgery in Lynch syndrome individuals. *Dueñas N, Navarro M, Teulé A, Solanes A, Salinas M, Iglesias S, Munté E, Ponce J, Guardiola J, Kreisler E, Carballas E, Cuadrado M, Matias-Guiu X, de la Ossa N, Lop J, Lázaro C, Capellá G, Pineda M, Brunet J.*
- GIT05. APC mosaicism as an underlying cause of unsolved familial adenomatous polyposis cases. *Rofes P, del Valle J, González S, Feliubadaló L, Pineda M, Tornero E, Menéndez M, Muñoz X, Montes E, Cuesta R, Navarro M, Solanes A, Dueñas N, Iglesias S, Salinas M, Balmaña J, Brunet J, Capellá G, Lázaro C.*
- GIT06. Study of non-coding RNAs of tumor microenvironment-derived exosomes in liquid biopsies samples as potential biomarkers in Colorectal and Pancreatic Cancer patients. *Galindo-Pumariño C, Collado-Valero M, Villalón-López J, Mendía E, Rodríguez-Garrote M, Longo F, Reguera P, Carretero I, Camino A, Carrato A, de la Pinta C, Peña C.*

- **GIT07. Liquid biopsy as a potential tool for clinical management in advanced Pancreatic Adenocarcinoma.** *Huerta M, Ferrer A, Roselló S, Tarazona N, Roda D, Gambardella V, Fleitas T, Garcés M, Muñoz E, Dorcaratto D, Sabater L, Alfaro-Cervello C, Martinez-Ciarpaglini C, Cervantes A, Ibarrola-Villava M.*
- **GIT08. Paired FFPE tumor and white blood cells samples variant calling analysis increases the number of candidate mutations to follow-up in circulating tumor DNA for tracking minimal residual disease in localized Colorectal Cancer patients.** *Martín-Arana J, Tébar-Martínez R, Tarazona N, Rentero-Garrido P, Carbonell-Asins JA, Martínez-Ciarpaglini C, Alfaro-Cervello C, Huerta M, Roselló S, Ferrer-Martínez A, Roda D, Zuñiga SM, Cervantes A.*
- **GIT09. Testing combination therapy in an MPNST precision medicine platform.** *Creus-Bachiller E, Fernández-Rodríguez J, Zhang X, Guha R, Thomas C, Musach J, Gel B, Pujana MA, Villanueva A, Serra E, Ferrer M, Lázaro C.*
- **GIT10. Genetic variability of the MHC class I and II and Pancreatic Cancer risk.** *Langtry A, Rabadian R, Filip I, López de Maturana E, Malats N.*
- **GIT11. TP53 pathogenic variants in Colorectal Cancer patients in absence of Li-Fraumeni-associated phenotypes.** *Terradas M, Mur P, Belhadj S, Valle L.*
- **GIT12. Benchmarking of microbiome detection tools on a synthetic database.** *Jurado F, Alonso L, Filip I, Rabadán R, Malats N.*
- **GIT13. Accumulation of genetic risk variants as cause of familial Colorectal Cancer.** *Mur P, Bonifaci N, Díez-Villanueva A, Munté E, Henar Alonso M, Aiza G, Navarro M, Piñol V, Brunet J, Tomlinson I, Capellá G, Moreno V, Valle L.*
- **GIT14. Characterization of pathological somatic mutations in circulating tumor DNA in localized Colon Cancer patients at diagnosis.** *Tébar-Martínez R, Martín-Arana J, Tarazona N, Seda E, Blesa S, Ferrer-Martínez A, Roselló S, Roda D, Huerta M, Martinez-Ciarpaglini C, Zuñiga S, Rentero-Garrido P, Cervantes A.*
- **GIT15. Characterization of the tumor-infiltrating immune repertoire in Urothelial Bladder Cancer.** *Benítez R, Yu K, Sirota M, Pineda S, Malats N.*

Hematological Tumours Research Programme

- **HT01. BCL2 inhibition licenses apoptosis and cooperates with anti-CD20 immunotherapy in mouse models of double-expressor lymphoma (DEL).** *Melchor J, García Lacarte M, Contreras S, Pascual M, Martínez Climent JA, Roa S.*
- **HT02. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of Multiple Myeloma.** *Garcés JJ, Bretones G, Burgos L, Valdes-Mas R, Puig N, Cedena MT, Alignani D, Rodriguez I, Álvarez Puente D, García Álvarez M, Goicoechea I, Rodriguez S, Calasanz MJ, Agirre X, Flores-Montero J, Sanoja-Flores L, Rodriguez-Otero P, Rios R, Martinez-Lopez J, Millacoy P, Palomera L, Del Orbe R, Pérez-Montaña A, El Omri H, Prosper F, Mateos MV, Rosiñol L, Blade J, Lahuerta JJ, Orfao A, Lopez-Otin C, San-Miguel J, Paiva B.*
- **HT03. Epigenetic loss of m1A RNA Demethylase ALKBH3 in Hodgkin Lymphoma targets collagen conferring poor clinical outcome.** *Esteve-Puig R, Climent F, Piñeyro D, Domingo-Domènech E, Dávalos V, Encuentra M, Rea A, Espejo-Herrera N, Soler M, Lopez M, Ortiz-Barahona V, Tapia G, Navarro JT, Cid J, Farré L, Villanueva A, Casanova I, Mangues R, Santamarina-Ojeda P, Fernández AF, Fraga MF, Piris MA, Kol N, Avrahami C, Moshitch-Moshkovitz S, Rechavi G, Sureda A, Esteller M.*
- **HT04. Molecular characterization of splicing altering variants in MDS.** *Boluda-Navarro M, Liquori A, Ibáñez M, Morote-Faubel M, González-Romero E, Sanz MA, Such E, Sanz G, Hutter S, Haferlach T, Cervera J.*
- **HT05. Measurable Residual Disease (MRD) in elderly Acute Myeloid Leukemia (AML): results from the PETHEMA-FLUGAZA Phase III Clinical Trial.** *Simoes C, Paiva B, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martínez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martínez-López J, Villar S, Calasanz MJ, Prosper F, San-Miguel J, Sanz MA, Montesinos P.*
- **HT06. Diffuse large B cell lymphoma genetic classification by targeted sequencing and associations with immunochemotherapy-treated patients' clinical outcome.** *Pedrosa Pérez L, Fernández-Miranda I, Pérez-Callejo D, Quero C, Rodríguez M, Martín-Acosta P, Gómez S, González-Rincón J, Santos A, Tarín C, García JF, García-Arroyo FR, Rueda A, Camacho FI, García-Cosío M, Heredero A, Llanos M, Mollejo M, Piris-Villaespesa M, Gómez Codina J, Yanguas-Casás N, Sánchez A, Piris MA, Provencio M, Sánchez-Beato M.*
- **HT07. Landscape and clinical significance of long non-coding RNAs involved in Multiple Myeloma expressed fusion transcripts.** *Amundarain A, Valcárcel LV, Ordoñez R, Garate L, Miranda E, Cendoya X, Carrasco-León A, Calasanz MJ, Paiva B, Meydan C, Mason CE, Melnick A, Rodriguez-Otero P, San-Miguel J, Planes FJ, Prósper F, Agirre X.*

- **HT08. Gene expression derived from alternative promoters improves prognostic stratification in Multiple Myeloma.** *Valcárcel LV, Amundarain A, Kulis M, Charalampopoulou S, Melnick A, San-Miguel J, Martín-Subero JI, Planes FJ, Agirre X, Prosper F.*
- **HT09. Altered phenotypic and functional immune profiles in Systemic Mastocytosis.** *Pérez-Pons A, Jara-Acevedo M, Henriques A, García-Montero AC, Álvarez-Twose I, Sánchez-Muñoz L, Matito A, Damasceno D, Muñoz-González JI, Caldas C, Navarro Navarro P, González López Ó, Escribano L, Mayado A, Orfao A.*
- **HT10. A method to predict risk of transformation in patients with Follicular Lymphoma.** *Fernández-Miranda I, Domínguez M, Pedrosa L, Gómez S, González-Rincón J, Espinet B, Climent F, de la Cruz F, Méndez M, García-Cosio M, Piris-Villaespresa M, García-Arroyo FR, Llano M, Yanguas-Casás N, Navarro B, Martín-Acosta P, Mollejo M, Piris MA, Provencio M, Sánchez-Beato M.*
- **HT11. Differentiation Therapy with Novel Epigenetic Inhibitors and their synergistic effect with chemotherapy drugs in Acute Myeloid Leukemia.** *Gimenez-Camino N, San José-Enériz E, Rabal O, Miranda E, Garate L, García F, Pineda-Lucena A, Paiva B, Muñoz J, San-Miguel J, Oyarzabal J, Agirre X, Prosper F.*
- **HT12. The genomic and transcriptomic landscape of the “chromatin-spliceosome” Acute Myeloid Leukemia (AML) clinical subgroup.** *Liquori A, Morote Faubel M, Ibáñez Company, Panadero Romero J, Sargas Simarro C, Boluda Navarro M, González Romero E, Martínez Valiente C, García Ruiz C, Santiago Balsera M, Sanjuán-Pla A, Such Taboada E, Montesinos Fernández P, Sanz Alonso MA, Barragán E, Sanz Santillana G, Cervera Zamora J.*
- **HT13. CRISPR/CAS9 mouse model to study cooperation between splicing and epigenetic alterations in Myelodysplastic Syndromes.** *Martínez-Valiente C, Gutiérrez-Adán A, García-Ruiz C, Rosón-Burgo B, González-Romero E, Liquori A, Barragan E, Cordón L, Boluda-Navarro M, Morote-Faubel M, Ibáñez M, Sanz MA, Sanz G, Cervera J, Sanjuan-Pla A.*
- **HT14. When to make clinical testing for the presence of a germline myeloid syndrome?** *Santiago M, Gil JV, Avetisyan G, Cordón L, Martín B, Liquori A, Ibáñez M, Mora E, Sargas C, González E, Boluda M, Morote M, Llop M, Montesinos P, Barragán E, Sanz MA, Sanz G, Zúñiga A, Such E, Cervera J.*
- **HT15. Mycosis Fungoides NanoString analysis.** *Alonso-Alonso R, Rodríguez M, García JF, García-Díaz N, Vaqué JP, Cereceda L, Rodriguez-Pinilla SM, Rodriguez-Peralto JL, Piris MA, Ortiz Romero P.*
- **HT16. Study of clonal hematopoiesis of indeterminate potential-associated mutations in patients with Myelodysplastic Syndromes.** *Toribio-Castelló S, Martín-Izquierdo M, Hernández-Sánchez M, Villaverde-Ramiro A, Santos-Mínguez S, Miguel-García C, González-Briones S, Rodríguez Iglesias I, González T, Benito R, Díez-Campelo M, Hernández-Rivas JM, Del Rey M.*
- **HT17. Minigene assays for the functional re-classification of splicing-affecting missense variants in Acute Myeloid Leukemia.** *Morote Faubel M, Liquori A, Ibáñez M, Boluda Navarro M, González Romero E, Martínez Valiente C, García Ruiz C, Santiago M, Avetisyan G, Sargas Simarro C, Llop García M, Barragán E, Sanjuán Pla A, Such E, Montesinos P, Senent L, Sanz MA, Sanz G, Cervera J.*
- **HT18. Waldenström’s Macroglobulinemia (WM) is preceded by Clonal Lymphopoiesis Including MYD88 L265P in progenitor B cells.** *Rodriguez S, Botta C, Celay I, Goicoechea I, Jimenez C, Garcia-Barchino MJ, Valdes R, Carrasco YR, Garces JJ, Larrayoz M, Santos S, Alignani D, Vilas A, Perez C, Garate S, Sarvide S, Lopez A, Reinhardt HC, Sanchez-Garcia I, Larrayoz MJ, Calasanz MJ, Prosper F, Motta M, Rossi G, Sacco A, Gentile M, Duarte S, Vitoria H, Geraldès C, Paiva A, Garcia-Sanz R, Roccaro AM, San-Miguel J, Martinez-Climent JA, Paiva B.*
- **HT19. Discordances between immunofixation (IFx) and Minimal Residual Disease (MRD) assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in patients (Pts) with multiple myeloma (MM): clinical and pathogenic significance.** *Rodriguez S, Goicoechea I, Gemenetzi K, Botta C, Agathangelidis A, Puig N, Cedena MT, Medina A, Valdes R, Garcés JJ, Perez JJ, Burgos L, Calasanz MJ, Alignani D, Vilas-Zornoza A, Sarvide S, Prosper F, Martinez-Climent JA, Orfao A, Garcia-Sanz R, Jimenez-Ubieto A, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, Chatzidimitriou A, San-Miguel J, Paiva B.*

Low prevalence Tumours Research Programme

- **LPT01. Bioprinted 3D models can reproduce different in vivo behaviors of Neuroblastoma by adjusting the model stiffness and cultured cells.** *Monferrer E, Vieco-Martí I, Samitier J, Noguera R.*
- **LPT02. Ectonucleotidases of the CD39 family regulate tumor cell proliferation in Endometrial Cancer.** *Rodríguez-Martínez A, Vidal A, Martín-Satué M, Matias-Guiu X.*
- **LPT03. Pap-smears allow the identification of diagnostic biomarkers for Endometrial Cancer.** *Coll-de la Rubia E, Martínez-García E, Reques A, Lesur A, Gil-Moreno A, Cabrera S, Dittmar G, Colas E.*

- **LPT04.** BioLight delivery to the very deep tissue via Bioluminescent Sphingomyelin Nanosystems (SNs) containing an encapsulated photosensitizer to provoke Photodynamic Therapy (PDT). *Abal-Sanisidro M, Alijas S, González-Blanco M, de la Fuente M.*
- **LPT05.** Evaluating the feasibility of CTC-cluster detection in diagnostic leukapheresis (DLA) products in Breast Cancer. *Martínez-Peña I, Franken A, Hurtado-Blanco P, Abuín-Redondo C, López-López R, Fehm T, Neubauer H, Piñeiro-Cid R.*
- **LPT06.** Penetration of antibody-targeted therapy in a 3D heterotypic spheroid model mimicking the architecture of Pancreatic Tumors. *Lores S, Bidan N, Alijas S, Mura S, López-López R, de la Fuente M.*
- **LPT07.** Targeted multifunctional nanoemulsions to interrupt metastatic progression of Non-Small Cell Lung Cancer. *Díez-Villares S, Alijas S, Fernández G, Vázquez-Ríos A.J, García-Sacristán A, González VM, López-López R, de la Fuente M.*
- **LPT08.** Study of vitronectin and its ligands expression and blockage of cell-extracellular interactions in Neuroblastoma cell lines. *Burgos-Panadero R, El-Moukhtarim S, Navarro-Fos S, Blanco-Prieto M, Noguera Salvá R.*
- **LPT09.** Analysis of circulating tumor cells and IGFBP-3 promoter methylation to predict chemotherapy response in advanced Non-Small Cell Lung Cancer patients. *Rodríguez-Casanova A, Juste T, Cortegoso A, García-González J, León-Mateos L, Anido U, Abalo A, Lago R, Mosquera-Presedo M, Bao-Caamano A, Pernia O, de Castro J, Ibáñez de Cáceres I, López-González L, Jiménez-Torres I, Muñelos-Romay L, López-López R, Diaz-Lagares A.*
- **LPT10.** Evaluation of the CellSearch and Parsortix systems to isolate CTCs for DNA methylation analysis in Colorectal Cancer. *Bao-Caamano A, Brozos-Vázquez E, Rodríguez-Casanova A, Abalo A, Lago-Leston R.M, Castillo-Sánchez M, Earl J, Longo F, Vidal-Insua Y, Vázquez-Rivera F, Candamio-Folgar S, López-López R, Muñelos-Romay L, Diaz-Lagares A.*
- **LPT11.** Zebrafish for the evaluation of innovative cancer nanomedicines. *Cascallar M, Lores S, Alijas S, Hurtado P, Martínez-Peña I, Piñeiro-Cid R, de la Fuente M*
- **LPT12.** Circulating cell-free DNA and Circulating Tumor Cells as prognostic biomarkers in advanced Non-Small Cell Lung Cancer patients treated with Pembrolizumab. *Mondelo-Macía P, García-González J, León-Mateos L, Aguín S, Abalo A, Anido U, Muñelos-Romay L, López-López R, Díaz-Peña R.*

- **LPT13.** PANIPAC- photoactivable nanoparticles to immunostimulate the tumor microenvironment in Pancreatic Cancer. *Saraiva SM, Abal-Sanisidro M, Lores S, Lopez JM, Cobo AG, Rodriguez LC, Arribas JL, López-López R, de la Fuente M.*

Mechanisms of Tumour Progression Research Programme

- **MTP01.** R-RAS2: a novel oncogene in ovarian cancer. *Clavaín L, Fernández-Pisonero M, Bustelo XR.*
- **MTP02.** CTHRC1 as a novel prognosis factor with oncogenic properties in Prostate Cancer. *Macchia A, Astobiza I, Ercilla A, Schaub-Clerigué A, Cortazar AR, Calvo F, Carracedo A, Torrano V.*
- **MTP03.** Characterization of alternative splicing dynamics in T-cell maturation and T-Cell Acute Lymphoblastic Leukemia. *Guillén Y, Espinosa L, Bigas A.*
- **MTP04.** Analysis of YAP and TAZ implication in HNSCC cell growth and gene expression. *Silva I, Segrelles C, Navarro M, Paramio JM, Lorz C.*
- **MTP05.** Identification of genomic and immune signatures to improve therapeutic strategy for high grade Serous Ovarian Cancer. *Lodewijk I, Bernardini A, Dueñas M, Suarez-Cabrera C, García-Martin R, Manso L, Paramio JM.*
- **MTP06.** VE-Cadherin modulates β-catenin/TCF-4 dependent genes to enhance Vasculogenic Mimicry. *Delgado-Bellido D, Zamudio-Martinez E, Herrera-Campos AB, Garcia-Diaz A, Oliver-Pozo FJ.*
- **MTP07.** Sublethal doses of DNA damaging agents induce a quiescent-like state with tumor initiation capacity in Colorectal Cancer patient-derived organoids. *Solé L, Lobo-Jarne T, Villanueva A, Guillén Y, Sangrador I, Vert A, Lop J, Guix M, Salido M, Bellosillo B, García-Romero R, Garrido M, Martínez-Iniesta M, Lopez-Arribillaga E, Salazar R, Montagut C, Torres F, Iglesias M, Celià-Terrasa T, Muñoz A, Bigas A, Espinosa L.*
- **MTP08.** Sur8 depletion impairs tumor development in a chemical colorectal cancer murine model. *López-Briones T, Ortega-Rodríguez J, Cámaras AB, Fernández-Barral A, Bustamante-Madrid P, Costales-Carrera A, Zarich N, Oliva JL, Barbáchano A, Muñoz A, Anta B, de Lucas MP, Rojas-Cabañeros JM.*
- **MTP09.** Comparative study of organoids from patient-derived normal and tumor Colon and Rectal tissue. *Fernández-Barral A, Costales-Carrera A, Bustamante-Madrid P, Domínguez O, Guerra-Pastrián L, del Peso L, Burgos A, Barbáchano A, Muñoz A.*

- **MTP10.** Plocabulin displays strong cytotoxic activity in a personalized Colon Cancer patient-derived 3D organoid assay. *Bustamante-Madrid P, Costales-Carrera A, Fernández-Barral A, Guerra L, Barbáchano A, Muñoz A.*
- **MTP11.** Inhibiting epigenetic machinery as a therapeutic approach for Bladder Cancer. *Nunes SP, Morales L, San José-Enériz E, Agirre X, Prosper F, Henrique R, Jerónimo C, Paramio JM.*
- **MTP12.** Quantitative population analysis and PD-L1 expression in tumours and healthy tissue from Bladder Cancer patients. *García-Martínez V, Bernardini A, Munera-Maravilla E, Lodewijk I, Dueñas M, Gómez del Cañizo C, Rodriguez-Izquierdo M, Guerrero-Ramos F, Paramio JM, Castellano D.*
- **MTP13.** Dual effect of epigenetic inhibitors and CAR-NK cell therapy in Bladder Cancer. *Morales L, Nunes SP, Munera-Maravilla E, Casado JA, Valeri A, San José-Enériz E, Agirre X, Prosper F, Paramio JM.*
- **MTP14.** Clonal heterogeneity analyses in childhood B-cell high hyperdiploid ALL show that high levels of double trisomy 18 and 10 are associated with a favorable prognosis. *Trincado JL, Ramos-Muntada M, Blanco J, Velasco-Hernández T, Gutierrez-Agüera F, Romecín PA, Rodríguez V, Swap C, Calasanz MJ, Cuatrecasas E, Camós M, Ortega M, Ballerini P, Nomdedeu J, Ramírez-Orellana M, Harrison C, Bueno C, Menendez P, Molina O.*
- **RTT05.** Spatial single-cell analysis: quantifying the impact of tissue microenvironment elements across subjects and conditions in endometrial cancer. *Jiménez-Sánchez D, Ariz M, Ortiz de Solórzano C.*
- **RTT06.** Circulating Tumor Cells as a surrogate marker of response in Non-Small Cell Lung Cancer. *Vilalta-Lacarra A, Baraibar I, Román M, Alonso I, Rodriguez-Remírez M, López-Erdozáin I, Gil-Bazo I.*
- **RTT07.** ID1 and PD-1 combined blockade impairs tumor growth and survival of KRAS-mutant Lung Cancer by stimulating PD-L1 expression and tumor infiltrating CD8+ T cells. *Rodríguez-Remírez M, Baraibar I, Román M, López-Erdozáin I, Vilalta-Lacarra A, Puyalto A, Torregrosa M, Guruceaga E, Lozano T, Alignani D, Ajona D, Pío R, Calvo A, Lasarte JJ, Gil-Bazo I.*
- **RTT08.** Characterization of molecular mechanisms involved in primary resistance to EGFR Tyrosine Kinase Inhibitors. *Coya JM, Álvarez E, Suárez R, Ferrer I, Paz-Ares L.*
- **RTT09.** Analysis of predictive and prognostic soluble biomarkers in advanced Non-Small Cell Lung Cancer (NSCLC) patients treated with anti-PD1/PDL1. *Gallach-García S, Garde-Noguera J, Torres S, Aparisi F, Vidal-Martinez J, Escorihuela E, Gisbert-Criado R, Moreno A, Ferrero M, Meri M, Sasheen I, Calabuig Fariñas S, Blasco Cordellat A, Honrubia-Peris B, García-Sánchez J, Jantus-Lewintre E, Camps C.*
- **RTT10.** CAFS and MMP-2 release the blockage of squamous cancer cell collective invasion due to FAK inhibition. *Celada L, Saénz de Santa María I, Chiara MD.*
- **RTT11.** A mouse lung cancer model of resistance to anti-C5aR1/anti-PD-1 combined therapy. *Senent Y, Remírez A, Ortiz-Espinosa S, Tavira B, Ajona D, Pio R.*
- **RTT12.** Identification of targetable alterations using NGS-based liquid biopsy in NSCLC patients. *Moreno-Manuel A, Gallach-García S, Calabuig-Fariñas S, Blasco-Cordellat A, Ferrero-Gimeno M, Ruiz-Cordero V, Torres Martínez S, Duréndez E, Mosqueda M, Escorihuela E, Fernández-Díaz A, Aparisi-Aparisi F, Jantus-Lewintre E, Camps C.*

Respiratory Tract Tumours Research Programme

- **RTT01.** Expression and clinical relevance of NANOG, SOX2 and OCT4 in Head and Neck Squamous Cell Carcinoma. *Granda-Díaz R, Pedregal-Mallo D, Hermida-Prado F, Montoro-Jiménez I, Allonca E, Pozo-Agundo E, Álvarez-González M, Álvarez-Fernández M, Álvarez-Marcos C, García-Pedrero JM, Rodrigo JP.*
- **RTT02.** Characterization of immunobiological properties of lung tumorspheres in NSCLC. *Torres S, Calabuig S, Ferrero M, Durendez E, Moreno A, Mosqueda M, Escorihuela E, Gallach-García S, Aparisi F, Guijarro R, Jantus-Lewintre E, Camps C.*
- **RTT03.** Prognostic significance of active SRC in patients with Head and Neck Squamous Cell Carcinoma. *del Río-Ibisate N, Granda-Díaz R, Hermida Prado F, Garmendia I, Montoro-Jiménez I, Pozo-Agundo E, Álvarez González M, Rodríguez R, Montuenga L, Rodrigo JP, García Pedrero JM.*
- **RTT04.** FOSL1 promotes Cholangiocarcinoma via direct and indirect regulation of genes involved in mevalonate synthesis and G2/M transition *Erice O, Vallejo A, Entralgo R, Feliu I, Guruceaga E, Perugorria MJ, Olaizola P, Macaya I, Ponz-Sarvise M, Calvisi DF, Banales JM, Vicent S.*

Organizing Committee

III Young Researchers Meeting

CIBERONC

CLAUDIA COSCA REQUENA

She takes part in the Gastrointestinal Tumours Research Programme. Claudia holds a BSc in Biostatistics and she is entering into her third year of the thesis. Her research is centered on the improvement of Pancreatic Cancer diagnosis through statistics methodology. She is working under the supervision of Dr. Núria Malats at the Spanish National Cancer Research Center (CNIO).

EVA M^a VERDUGO SIVIANES

She belongs to the Respiratory Tract Tumours Research Programme. Eva, BSc in Biotechnology, has recently defended her doctoral thesis. She is currently a postdoc in the group of Dr. Amancio Carnero at the Institute of Biomedicine of Seville (IBIS). Her work focuses in the search and identification of mutations in those genes determining the dedifferentiation to CSCs and the tumoural resistance to treatment.

MANUEL GÁMEZ CHIACHIO

He is part of the Breast Cancer Programme. Manu has a BSc in Biochemistry and he is currently in his second year of thesis researching the role of Gasdermin-B in HER2+ Breast Cancer in the group of Dr. Gema Moreno at the "Alberto Sols" Biomedical Research Institute (IIBM).

IZASKUN MIGUEL GARCÍA

Deputy Director of CIBERONC.

SANDRA DÍEZ VILLARES

She takes part in the Low Prevalence Tumours Programme. Sandra has a BSc in Chemistry and she is currently doing her third year of thesis studying the development of nanoparticles to improve cancer diagnosis under the supervision of Dr. María de la Fuente and Dr. Rafael López at the Complejo Hospitalario Universitario de Santiago (CHUS).

PILAR BUSTAMANTE MADRID

She is part of the Mechanisms of Tumour Progression Research Programme. Pilar is a biochemist moving into her third year of the thesis researching about the effects of vitamin D on Colon Cancer in the group of Professor Alberto Muñoz Terol at the "Alberto Sols" Biomedical Research Institute (IIBM).

NOELIA DASILVA FREIRE

She belongs to the Hematological Tumours Programme. Noelia holds both a BSc in Biotechnology and a MSc in the Biology and Clinics of Cancer. She is about to finish her thesis about the mutational and immunophenotypic characterization of Systemic Mastocytosis under the supervision of Professor Alberto Orfao at the Cancer Research Center (CIC) of Salamanca.

Contact



<https://www.ciberisciii.es/>
<https://www.ciberonc.es/>

<https://encuentrojovenesinvestigadores.ciberonc.es/>



@CIBER_ISCIII y @CIBERONC
#IIIIEJI_ONC



@ciber_investiga



https://www.youtube.com/watch?v=kBAKQa_jH0k&feature=emb_title

Contact Information

Izaskun Miguel García, PhD
Deputy Director of CIBERONC
adjuntadireccion@ciberonc.es
Phone: (+34) 689.94.54.64

